Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation

NCT ID: NCT03059043

Last Updated: 2024-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-16

Study Completion Date

2026-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety and efficacy of a viscoelastic-free method for Implantable Collamer Lens(ICL) implantation to treat high myopia. The subjects undergo randomization of ICL implantation using the viscoelastic-free method on one eye and undergoing standard method on the other one. The post-operative data are collected for analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Implantable Collamer Lens(ICL) implantation has been proved to be an effective refractive option for surgical correction of high myopia. Currently, standard method utilizing the viscoelastic agent to fill and maintain the anterior chamber during the implantation, this requires an additional step to remove the viscoelastic agent at the end of the surgery and may cause the intraocular pressure spike in the early post-operative phase due to the incomplete removal of the viscoelastics. The new method is viscoelastic-free, which can be achieved by using balanced salt solution irrigation during the implantation.

This study is a prospective, randomized, paired-eye study to compare the safety and efficacy of the viscoelastic-free method with the standard method. Subjects enrolled in the study will be randomized to receive viscoelastic-free method on one eye and undergo standard method on the other one.The clinical outcomes of two groups will be assessed at several follow-ups: 2 hours, 1 day, 1 week, 1 month, 3 months and 6 months post-operatively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

viscoelastic-free system

Eyes in this group will use viscoelastic-free implantation system during the surgery

Group Type EXPERIMENTAL

viscoelastic-free implantation system

Intervention Type DEVICE

Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation

viscoelastic-assisted system

Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery

Group Type ACTIVE_COMPARATOR

standard viscoelastic-assisted Implantation system

Intervention Type DEVICE

This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

viscoelastic-free implantation system

Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation

Intervention Type DEVICE

standard viscoelastic-assisted Implantation system

This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented stable refraction for at least 1 year(within 0.5D)
* Best spectacle-corrected visual acuity (BCVA) of 20/40 or better
* Clear central cornea
* -0.5D to -18.0D of myopic refractive error
* Normal anterior chamber depth at least 2.8 mm to endothelium
* Endothelial cell density (ECD) more than 2000 cell/mm2
* Pupil diameter smaller than 7.0 mm under mesopic condition
* Discontinued 3 weeks for hard contact lens and 1 week for soft contact lens wear

Exclusion Criteria

* Preexisting ocular diseases or conditions other than myopia, evidence of progressive or acute ocular disease
* Evidence of connective tissue disease or other systemic diseases that may confound the results of the study;
* Narrow angle of anterior chamber
* Pregnant, lactating, or planning to become pregnant during the course of the trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wenzhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

A-Yong Yu

Director of the Cataract Clinical Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AYong Yu, MD. PhD.

Role: PRINCIPAL_INVESTIGATOR

Wenzhou Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guangdong General Hospital

Guangzhou, Guangdong, China

Site Status NOT_YET_RECRUITING

Hunan Provincial People's Hospital

Changsha, Hunan, China

Site Status NOT_YET_RECRUITING

The Eye Hispital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status RECRUITING

Peking Union Medical College Hospital

Beijing, , China

Site Status NOT_YET_RECRUITING

Shanghai Ninth People's Hospital

Shanghai, , China

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

AYong Yu, MD. PhD.

Role: CONTACT

+86-0577-88068880

Anpeng Pan, MD.OD.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jin Zeng, MD.

Role: primary

Hua Wang, MD.

Role: primary

Anpeng Pan, MD.OD.

Role: primary

+86-577-88068809

Yan Luo, MD.

Role: primary

Jibo Zhou, MD.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20170121

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vault Evaluation After ICL Implantation
NCT06229119 COMPLETED PHASE4